title: Impact of rhBMP-2 on regeneration of buccal alveolar defects during the osseointegration of transgingival inserted implants.
abstract: OBJECTIVE
  New approaches to enhance vertical bone regeneration in clinically relevant implant models are needed. Therefore, we analyzed the impact of recombinant human bone morphogenic protein 2 (rhBMP-2) on the healing of large buccal alveolar defects during osseointegration of transgingivally inserted implants.
  
  
  METHODS
  Twenty-four dental implants were inserted transgingivally in the mandibles of 6 labrador/golden retriever cross-bred dogs. Before implantation, a standardized buccal bone defect was created and refilled with either calcium phosphate as a carrier containing rhBMP-2 or calcium phosphate alone. Either ceramic abutments that enabled immediate implant loading or healing distance collars to prevent loading were mounted. Sixteen weeks after intervention, bone implant units were analyzed by radiofrequency analysis and histomorphometry.
  
  
  RESULTS
  In total, 14 implants (58.3%) were available for further analysis. The mean depth of the bone defects, the gain of regenerated bone, the vertical osseointegration of the implants, and the bone-to-implant contact in the newly formed bone were slightly greater in the rhBMP-2-containing samples. In contrast, the osseointegration in the preexisting bone was even superior within the non-rhBMP-2-treated specimen. However no differences were statistically significant.
  
  
  CONCLUSIONS
  When rhBMP-2-conducted bone regeneration was compared with control samples, no significant differences of newly formed bone were found at the bone-implant interface. The amounts of rhBMP-2 applied do not seem suitable to enhance implant osseointegration in large buccal defects.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University Hospital Aachen, Aachen, Germany. rasmeets@ukaachen.de
authors.forename: Ralf
authors.initials: R
authors.lastname: Smeets
authors.forename: Oliver
authors.initials: O
authors.lastname: Maciejewski
authors.forename: Markus
authors.initials: M
authors.lastname: Gerressen
authors.forename: Hubertus
authors.initials: H
authors.lastname: Spiekermann
authors.forename: Oliver
authors.initials: O
authors.lastname: Hanisch
authors.forename: Dieter
authors.initials: D
authors.lastname: Riediger
authors.forename: Felix
authors.initials: F
authors.lastname: Blake
authors.forename: Jamal
authors.initials: J
authors.lastname: Stein
authors.forename: Frank
authors.initials: F
authors.lastname: Hölzle
authors.forename: Andreas
authors.initials: A
authors.lastname: Kolk
mesh_terms: D016301:Alveolar Bone Loss / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D000818:Animals; D001857:Bone Matrix / Q000473:pathology; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects*; D002130:Calcium Phosphates; D002516:Ceramics / Q000737:chemistry; D000044:Dental Abutments; D015921:Dental Implants; D003764:Dental Materials / Q000737:chemistry; D017267:Dental Prosthesis Design; D004285:Dogs; D004337:Drug Carriers; D006801:Humans; D008297:Male; D008334:Mandible / Q000473:pathology / Q000601:surgery; D008336:Mandibular Diseases / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D016348:Osseointegration / Q000502:physiology*; D010006:Osteoblasts / Q000473:pathology; D010012:Osteogenesis / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013499:Surface Properties; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D015921:Dental Implants; D003764:Dental Materials; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; C020243:calcium phosphate